<div>The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.</div>

The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.

Rare Disease Report: The FDA Decision for Pompe Disease Therapy

<div>Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.<br>
<br>
<br>
<br>

</div>

News

Science

Medicine

Health & Fitness

Business News

Life Sciences

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.<br>
<br>
<br>
<br>



Share Rare Disease Report: The FDA Decision for Pompe Disease Therapy

Sign up to save your podcasts

Rare Disease Report: The FDA Decision for Pompe Disease Therapy

Rare Disease Report: The FDA Decision for Pompe Disease Therapy